Category: News

Every second week we invite a leading fund manager to present at The Insider: Meet the Fund Manager. In October, Merchant Funds’ Andrew Chapman selected Race Oncology as one of his favourite stocks, regarding the company’s Zantrene® as a ‘first-in-class,…

Yesterday’s 25 basis point rate hike was largely expected by economists, but it was RBA governor Philip Lowe’s outlook of a 3.85% terminal cash rate that slightly stunned the market – with Australian equities pulling back and the dollar spiking. The ASX 200 was less than 1% off it’s all time high on Monday, but has since retreated to 1.5% away from its April 2022 record.

Almost 60 years since they established an Australian subsidiary that turned into the country’s biggest gold miner, Newmont Corporation (NYSE: NEM) wants to bring Newcrest Mining (ASX: NCM) back under its control in what would be one of the biggest gold consolidations in Australian history. 

Guess what’s not being made in China. Enough babies. China has been losing ground to its neighbour just over the Himalayas, India in terms of population growth. Chinese authorities in Hong Kong took this as a cue to contact recently married women, inquiring whether they expect to be expecting.

Far East Gold (ASX: FEG) is wasting no time advancing their flagship Woyla project. After making a major greenfield discovery in December last year, the company now has three rigs operating at two of the project’s prospects, with the goal of defining a resource. All assays from the phase one drilling campaign have been received, and reaffirm the company’s belief that Woyla is highly prospective to contain a high-grade gold and silver epithermal deposit.

Cancer therapy has historically been limited to the three pillars of treatment – surgery, chemotherapy and radiation. Each poses their own benefits, risks and limitations. Together with better diagnosis, these three pillars have been refined over many decades to the point where some cancers are not necessarily considered “the death sentence it used to be”. However, there were still almost 10 million deaths worldwide attributable to cancer in 2020 – and over 18 million cases diagnosed globally that year.

Every second week we invite a leading fund manager to present at The Insider: Meet the Fund Manager. In October, Merchant Funds’ Andrew Chapman selected Dimerix as one of his favourite stocks, highlighting the company as being, at the time,…

After making a major greenfield discovery at their flagship Woyla project, Far East Gold (ASX: FEG) finished up the second quarter of FY23 with a plan to launch into a resource definition drilling campaign that will hopefully provide a tangible glimpse of the significant gold-silver resource potential that FEG has confirmed Woyla possesses.

If 2022 was the year in which Propell (ASX: PHL) launched itself on the pathway to profitability, 2023 might be when it gets to significantly pick up speed, according to the company’s recently announced Q2 FY23 quarterly activities report.

In the lead up to this week’s The Insider: Meet the Fund Manager, Graeme Carson from Cyan Investment Management sat down with Reach Markets to provide a bit of information about his investment strategy, industries of interest and view on the market.

Some call it the ‘least bad option’, some a ‘dumb idea that won’t go away’. But perhaps it was beloved fictional character Homer J. Simpson who summed it up perfectly when he said, “Ooo a trillion dollar bill, that’s a spicy meatball!”

COVID may have dominated headlines in 2020 causing at least 3 million deaths as reported by the World Health Organisation, but in the same year nearly 10 million lives were lost to a much deadlier adversary – cancer. Fighting back is clinical-stage biotech company Prescient Therapeutics (ASX: PTX).